Comparison of the cytotoxic response against ovarian cancer by immune effector cells isolated and expanded from normal donors and ovarian cancer patients

Cytotherapy

Volumn 14, Issue 6, 2012, Pages 716-723

  Ingersoll, Susan Blaydes ^a,b   Stoltzfus, Gregory P ^a   Merchant, Mohammed H ^a   Ahmad, Sarfraz ^a,b,c   Edwards, Collin R ^a   Ahmed, Ahad ^a   Oyer, Jeremiah L ^a   Finkler, Neil J ^a,b,c   Holloway, Robert W ^a,b,c   Edwards, John R ^c,d  

^a FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^b FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^d Lifeforce Cryobanks   (United States)

Author keywords

Cell expansion; Cytokines; Cytotoxicity; Ovarian cancer; T cells

Indexed keywords

ALPHA2B INTERFERON; CD3 ANTIBODY; INTERLEUKIN 2;

ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER PATIENT; CELL MEDIATED CYTOTOXICITY; CELL SELECTION; COCULTURE; CONTROLLED STUDY; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; NATURAL KILLER CELL; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 84862200283     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2012.663484     Document Type: Article

References (26)

1. cGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6. (Pubitemid 26012496)
2. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203-13. (Pubitemid 36077915)
3. Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev. 2008;222:101-16. (Pubitemid 351430376)
4. Ingersoll SB, Patel S, Caballero L, Ahmad S, Edwards D, Holloway RW, Edwards J.R. Synergistic cytotoxicity of interferonalpha-2b and interleukin-2 in combination with PBMC against ovarian cancer: development of an experimental model for cellular therapy. Gynecol Oncol. 2009;112: 192-8.
5. Ingersoll SB, Ahmad S, Stoltzfus GP, Patel S, Radi MJ, Finkler NJ, et al. Functional characterization of a fl uorescent highly tumorigenic ovarian cancer line to test cellular therapy in experimental models. Int J Gynecol Cancer. 2011;21: 457-65.
6. Ayello J, van de Ven C, Cairo E, Hochberg J, Baxi L, Satwani P, Cairo MS. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Exp Hematol. 2009;37:1216-29.
7. Korzeniewski C, Callewaert DM. An enzyme-release assay for natural cytotoxicity. J Immunol Meth. 1983;64:313-20. (Pubitemid 14243095)
8. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Meth. 1988;115:61-9.
9. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 1996;2:1096-103. (Pubitemid 26338628)
10. + T regulatory cells: role of tumor-derived TGF-beta. J Immunol. 2007;178: 2883-92. (Pubitemid 46333166)
11. . Curiel TJ. Tregs and re-thinking cancer immunotherapy. J Clin Invest. 2007;117:1167-74.
12. Quesnel B. Tumor dormancy and immunoescape. Acta Pathol. Microbiol. Immunol. Scand. APMIS. 2008;116:685-94.
13. . Saunier EF, Akhurst RJ. TGF-beta inhibition for cancer therapy. Curr Cancer Drug Targets. 2006;6:565-78.
14. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765. (Pubitemid 32368050)
15. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol. 1998; 64:275-90. (Pubitemid 28409233)
16. Liu Z, Guo B, Lopez RD. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer. J Gastroenterol Hepatol. 2009;24:900-11.
17. Piali L, Hammel P, Uherek C, Bachmann F, Gisler RH, Dunon D, Imhof BA. CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol. 1995;130:451-60.
18. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, et al. Induction of antigen-specifi c T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA. 1998;95:1178-83. (Pubitemid 28124932)
19. Rodr í guez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008;222: 180-91. (Pubitemid 351430370)
20. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13:98-107.
21. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin- cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58:49-59.
22. Almand B, Clark JI, Nikitina E, van Beyen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166:678-89. (Pubitemid 32038493)
23. Carlsten M, Bj ör kstr öm NK, Norell H, Bryceson Y, van Hall T, Baumann BC, et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 2007;67:1317-25.
24. S atwani P, van de Ven C, Ayello J, Cairo D, Simpson LL, Baxi L, Cairo MS. Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 signifi -cantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function. Cytotherapy. 2011;13:730-8.
25. Raulet DH, Held W. Natural killer cell receptors: the offs and ons of NK cell recognition. Cell. 1995;82:697-700.
26. . Kä r re K. Express yourself or die: peptides, MHC molecules, and NK cells. Science. 1995;267:978-9.